The Role of Brain Inflammation in Epileptogenesis in TSC
Final rept. 1 Jul 2012-30 Jun 2014
WASHINGTON UNIV ST LOUIS MO
Pagination or Media Count:
Epilepsy is a common, disabling problem in patients with tuberous sclerosis complex TSC and is usually intractable to available treatments. This Exploration-Hypothesis Development Award investigates the hypothesis that inflammation contributes to epileptogenesis in an animal model of TSC and that anti-inflammatory drugs may represent rational, effective therapies for epilepsy in TSC. In the first grant year, we have identified a series of inflammatory cytokines and chemokines, such as interferon IL1-beta and CXCL10, based on polymerase chain reaction, western blotting, and immunohistochemistry, which are elevated in a mouse model of TSC. Furthermore, these inflammatory markers could be reversed by the mammalian target of rapamycin mTOR inhibitor, rapamycin. These findings suggest that these inflammatory mediators could be involved in epileptogenesis in the mouse model and support the testing of anti-inflammatory agents that inhibit these mediators as potential treatments for epilepsy in the mice.
- Anatomy and Physiology
- Medicine and Medical Research